Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Nirmatrelvir

An antiviral that blocks the main protease (Mpro) of SARS-CoV-2, the enzyme the virus uses to cut its own proteins and multiply; it is taken together with ritonavir and was authorised in the United States in December 2021 against COVID-19. This family brings together the active ingredient, metabolites, labelled standards and other impurities.

Did you know?Its partner, ritonavir, born as an HIV medicine, does not act on the coronavirus: it blocks the CYP3A enzyme that would break nirmatrelvir down, so raising its levels in the blood.

NirmatrelvirGo to the active ingredient →
NirmatrelvirActive ingredientNirmatrelvirCat. No. P-N071-001CAS 2628280-40-8

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.